New research suggests that certain genetic variants, carried by around 10 percent of the population, may be making type 2 diabetes GLP-1 treatments less effective. The study involved an enzyme called PAM (PAM), which can interfere with the activation of hormones like GLP1. The researchers compared 19 people with the PAM gene variant p.S539W to 19 matched controls and found that it was creating GLPA-1 resistance, preventing the hormone from being properly processed by the body. The findings supported the idea that these genetic variants lead to GLP.-1 resistance. The research could potentially help determine whether or not these treatments will work for individuals with type 2 Diabetes.